Aurobindo Pharma surged 5% after reports said GTCR, not Aurobindo, will acquire Zentiva for $4.8 billion, easing debt worries. Visible short covering added momentum. SEBI analyst Ashok Kumar Aggarwal set short-term buy targets of ₹1,190-1,250 with support at ₹1,102-1,110 and stop loss at ₹1,050. Retail sentiment on Stocktwits turned bullish after the news.